"Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Feb 2021 · 1 min read
In brief
In brief
This review examines the complement cascade's role in hepatocellular carcinoma pathogenesis, exploring how dysregulated complement activation creates immunosuppressive tumor microenvironments. The authors analyze specific complement proteins as potential therapeutic targets in HCC, addressing the urgent need for non-palliative treatments beyond current surgical and medical options.
Written by the GCMD Library team from the article.
Statements in this article
Hepatocellular carcinoma is the most common primary malignancy of the liver and a leading cause of death in the US and worldwide.
Even with surgical interventions and newer medical treatment regimens, patients with HCC have poor survival rates.
The liver microenvironment in HCC is intricately associated with chronic necroinflammation, progressive fibrosis, and cirrhosis as precedent events along with dysregulated innate and adaptive immune responses.
The liver is the primary source for biosynthesis of >80% of complement components and expresses a variety of complement receptors.
Recent studies implicate the complement system in liver inflammation, abnormal regenerative responses, fibrosis, carcinogenesis, and development of HCC.
Complement activation differentially promotes immunosuppressive, stimulant, and angiogenic microenvironments conducive to HCC development.